Themed Salon | Antibody Discovery: The First Step in Developing Novel Antibody Drugs
Release Date:
2023-09-08 13:36
Introduction to the Themed Salon
Antibody drugs currently represent the fastest-growing segment within the biopharmaceutical industry and are a major focus of global drug research and development. The rapid advancement of antibody therapeutics has been driven by technological innovations, such as: Various display technologies, transgenic humanized animals, single-cell PCR, and single-cell sequencing Wait.
The first session, hosted by Shanghai Heyan Biotechnology Co., Ltd. and co-organized by Shanghai Municipal School of Pharmacy, Shanghai Hycells Biotechnology Co., Ltd., and the Pharmaceutical Source Research & Development Workshop, is free of charge. Thematic Salon—Antibody Discovery: The First Step in Developing Novel Antibody Drugs The event will be held in Shanghai on the afternoon of September 16, 2023. Industry peers and R&D professionals in the fields of antibody discovery and new drug development are warmly invited to register and participate, so that we can jointly explore the research and development of antibody therapeutics.
Salon Schedule (September 16)
Antibody Discovery: The First Step in Developing Novel Antibody Therapeutics
13:30–14:00 Registration
14:00–14:10 Event Introduction
01
14:10-14:40
Cell Therapy and CAR-T–Related Antibody Discovery
Wang Peng, Founder of Xichang Bio
02
14:40-15:20
Development and Application of Phage Display Technology
Zhou Chen, Founder of Shuangzhan Bio
15:20–15:40 Tea Break
03
15:40-16:20
Progress in the Development and Application Research of Nanobody Technology
Li Shenghua, Chief Scientist, NuAnBo Biotechnology
04
16:20-16:40
Multi-species gene-edited animals
Empowering Antibody Drug Discovery
Zhang Jiwei, CEO
Related News
HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)
Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.
HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)
The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.
This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board